Raptor Pharmaceutical (RPTP +16%) surges to a new 52-week high today, after the company reported...

|About: Raptor Pharmaceutical Corp. (RPTP)|By:, SA News Editor

Raptor Pharmaceutical (RPTP +16%) surges to a new 52-week high today, after the company reported late yesterday that the FDA's Office of Orphan Product Development has granted seven-year orphan drug exclusivity for Procysbi delayed-release capsules for the management of nephropathic cystinosis. The exclusivity period began on the date of the drug's initial FDA approval, April 30.